A vaccine with gold nanoparticles loaded with a Listeria peptide for the treatment and prevention of melanoma

Developed by: Fundación Instituto de Investigación Marqués de Valdecilla

Description

IDIVAL has developed a vaccine with gold nanoparticles loaded with a Listeria peptide for the treatment and prevention of melanoma. This vaccine achieves a tumor regression of 90% and it also prevents in more than 95% the formation of metastases in the lungs. This vaccine might be a useful alternative treatment for advance melanoma, alone or in combination with other therapies.

Results tested in mice. Currently, the vaccine is being developed at Valdecilla Biomedical Research Institute– IDIVAL.

Applications

Cancer immunotherapy treatments.

Estado de protección

A patent application covering this technology has been filed through Spanish patent application ES201600160. 

Desired cooperation

IDIVAL would like to talk to companies interested in commercializing this vaccine or in a research cooperation agreement to develop it.

Status:
En desarrollo, Transferible
Health technology:
Medicamentos - Farma